Built on studies.
Not hype.

Every active is disclosed with its exact dose. Explore the human evidence behind the ingredients, how closely each study matches Ava, and where the science is still developing.

Abstract black and white cellular texture Evidence, read in context.
16Disclosed active nutrients
3Functional systems
0Proprietary blends
3rdParty tested

Context changes
the conclusion.

“Science-backed” means little without the study design, population, ingredient form and dose. We show the match as well as the limitations.

01

Human evidence first

Randomised human trials carry more weight than mechanisms or laboratory findings alone.

02

Dose and form matter

We compare the researched amount and extract specification with the amount and form in Ava.

03

Limitations stay visible

Mixed findings, small samples and different populations are shown—not edited out.

Sustained support,
without the spike.

Ava designTypical stimulant profile

Illustrative model only. This graph explains the formulation strategy; it is not measured clinical outcome data for the finished Ava product and does not predict an individual response.

Find the
evidence.

Search selected human trials and evidence reviews relevant to Ava’s ingredients. Filter by ingredient or by the role it plays in the formula.

Reviews may include trials listed separately. The entry count is not a count of independent experiments.

Ingredient
Function
40 research entries shownStudies open on PubMed in a new tab
CiticolineRCT · 1996

Citicoline and verbal memory in older adults

95 older adults · 1,000 mg/day · 3 months

The initial benefit was limited to participants with less efficient memory. A 32-person follow-up used 2,000 mg/day. Both doses exceed ava’s 500 mg; this is not evidence for all age groups.Read study
CiticolineRCT · 2019

Citicoline and attention in adolescent males

75 participants · 250 or 500 mg/day · 28 days

Attention and motor-speed measures improved versus placebo. This short study involved adolescent males and a specific citicoline product; it does not establish adult outcomes or recommend ava for children.Read study
Nicotinamide ribosideCrossover RCT · 2018

NR and NAD+ in healthy older adults

24 completed · 1,000 mg/day · 6 weeks per treatment

NR increased blood-cell NAD+ and was generally well tolerated. This biomarker result is not proof of better everyday energy; the dose was above ava’s 300 mg.Read study
Nicotinamide ribosideRCT · 2018

NR and metabolic outcomes in men with obesity

40 men · 2,000 mg/day · 12 weeks

No improvement in insulin sensitivity, resting energy expenditure or body composition versus placebo. The population and dose differ from ava; NAD+ biology does not guarantee a metabolic benefit.Read study
Nicotinamide ribosideCrossover RCT · 2020

NR and muscle metabolism

13 adults · 1,000 mg/day · 6 weeks per treatment

Some muscle metabolites changed, but insulin sensitivity and mitochondrial function did not improve. A small trial in overweight or obese adults, at a higher dose than ava.Read study
Lion’s maneRCT · 2019

Lion’s mane and cognitive test performance

Fruiting-body supplement · 12 weeks

One of three cognitive tests improved; the other tests did not show the same benefit. This preparation was not ava’s extract, and the trial does not establish dementia prevention.Read study
Lion’s maneRCT · 2010

Lion’s mane and self-reported mood

30 women randomised · 2 g/day powder · 4 weeks

Some individual symptom scores differed, but overall depression and sleep-score changes did not significantly differ from placebo. Only 26 participants were analysed; powder is not equivalent to ava’s extract.Read study
Coenzyme Q10RCT · 2008

CoQ10 and exercise endurance

41 adults · 200 mg/day · 14 days

Blood CoQ10 increased, but the endurance finding was a non-significant trend (p = 0.06). The fast-melt preparation and 200 mg dose differ from ava’s 100 mg.Read study
Coenzyme Q10Controlled trial · 2013

Ubiquinol and power output in trained athletes

100 athletes · 300 mg/day · 6 weeks

Power at the tested lactate threshold improved more than placebo during training. This used ubiquinol, not ava’s ubiquinone, at three times the dose; the forms cannot be assumed equivalent.Read study
Acetyl-L-carnitineRCT · 2008

Acetyl-L-carnitine and fatigue in older patients

96 participants · Ages 71–88 · Clinical population

The authors reported improvements in fatigue and function. Results in older patients cannot establish everyday benefits in healthy younger adults; the abstract does not specify the dose or duration.Read study
Acetyl-L-carnitineOpen-label trial · 2004

Carnitine forms in chronic fatigue syndrome

90 patients · ALCAR arm: 2 g/day · 24 weeks

Mental-fatigue scores improved in the acetyl-L-carnitine arm, but there was no placebo group or blinding. Clinical population and dose differ substantially from ava; no treatment benefit for ava is established.Read study
N-Acetyl-L-CysteineMeta-analysis · 2017

NAC and exercise performance: pooled evidence

7 performance studies · 17 side-effect studies

The pooled performance estimate was small and its confidence interval included no effect. Doses and administration methods varied; these findings do not establish a benefit from ava’s 600 mg oral dose.Read analysis
N-Acetyl-L-CysteineMeta-analysis · 2022

NAC and recovery biomarkers

37 papers · 1,388 participants

Acute NAC did not significantly improve lactate, oxygen uptake or several other recovery markers. Biomarker research with varied protocols is not proof of better recovery from ava.Read analysis
N-Acetyl-L-CysteineCrossover RCT · 2019

NAC during repeated cycling efforts

11 trained cyclists · 20 mg/kg · Acute oral dosing

No improvement in either cycling performance test versus placebo. This small trial used body-weight-based dosing and a specific exercise protocol, not ava’s daily formulation.Read study
AstaxanthinRCT · 2012

Astaxanthin and age-related forgetfulness

96 adults · 6 or 12 mg/day · 12 weeks

Some scores improved over time, but the trial did not establish a significant cognitive difference versus placebo. Studied doses bracket ava’s 8 mg; matching the ingredient alone is not enough.Read study
AstaxanthinControlled trial · 2018

Astaxanthin source and cognitive outcomes

54 participants · 8 mg/day · 8 weeks

No significant overall differences on cognitive tests; an age subgroup showed a signal. The bacterial extract also differs from ava’s ingredient source, despite the matching 8 mg dose.Read study
AstaxanthinRCT · 2011

Astaxanthin and cycling time-trial performance

21 randomised · 4 mg/day · 28 days

Cycling time improved versus placebo, but only 14 riders completed the trial. A small sport-specific result at half ava’s dose does not establish a general energy benefit.Read study
Rhodiola roseaRCT · 2009

Rhodiola in stress-related fatigue

60 participants · SHR-5 576 mg/day · 28 days

Some fatigue and attention measures improved versus placebo. Participants had fatigue syndrome; this standardised extract and dose differ from ava’s 75 mg and do not establish a treatment claim for ava.Read study
Rhodiola roseaSystematic review · 2012

Rhodiola: physical and mental fatigue review

11 controlled studies · Mixed populations

Findings were inconsistent. All included studies had high or unclear risk of bias, so the review could not establish reliable fatigue benefits; it is not evidence for ava’s finished formula.Read review
Rhodiola roseaCrossover RCT · 2013

Rhodiola before a cycling time trial

18 participants · 3 mg/kg · Single dose

Cycling time and perceived exertion improved, but cognition and other measures did not significantly change. A small acute trial with weight-based dosing, not a test of ava’s 75 mg serving.Read study
Panax ginsengCrossover trial · 2005

Ginseng during sustained mental effort

30 healthy adults · G115 200 or 400 mg · Single dose

The 200 mg dose improved one arithmetic task and perceived mental fatigue. Small, task-specific findings with G115 cannot be transferred directly to ava’s 75 mg ginseng.Read study
Panax ginsengCrossover RCT · 2010

Ginseng, working memory and calmness

30 adults · G115 200 or 400 mg/day · 8-day periods

Effects depended on dose: 400 mg improved some measures, while 200 mg slowed arithmetic responses. Repeated use added no clear benefit; extract and doses differ from ava.Read study
Panax ginsengRCT · 2013

Ginseng in idiopathic chronic fatigue

90 participants · 1 or 2 g/day extract · 4 weeks

Total fatigue scores did not significantly differ from placebo; some mental-fatigue measures improved. Clinical population and gram-level doses differ substantially from ava’s 75 mg.Read study
Panax ginsengCochrane review · 2010

Ginseng and cognition: evidence review

9 eligible trials · 5 with extractable results

The review found insufficient convincing evidence for cognitive enhancement in healthy people. Different doses, products and tests prevented pooled analysis; selected positive trials do not settle the question.Read review
CiticolineRCT · 2021

Citicoline and memory in healthy older adults

100 participants · 500 mg/day · 12 weeks

Relevant dose; population had age-associated memory impairment.Read study
Nicotinamide ribosideRCT · 2019

Safety and NAD+ metabolism

140 participants · 100–1,000 mg/day · 8 weeks

Shows a biomarker effect; does not establish a subjective energy benefit.Read study
Lion’s maneRCT · 2009

Lion’s mane in mild cognitive impairment

30 participants · 3 g/day powder · 16 weeks

Promising outcome; form, dose and population differ from Ava.Read study
Lion’s maneCrossover RCT · 2025

Lion’s mane: acute cognition and mood

18 healthy adults · 3 g extract · Single dose

No overall improvement in cognition or mood; one motor-task result improved. The 3 g, 10:1 extract differs from ava’s 750 mg fruiting-body extract.Read study
Lion’s manePilot RCT · 2023

Lion’s mane in healthy young adults

41 completed · 1.8 g/day · 28 days

A faster Stroop-task result, but mixed memory findings and no clear overall cognitive benefit. The stress finding was a non-significant trend. Dose and mushroom preparation differ from ava.Read study
Coenzyme Q10Crossover RCT · 2008

CoQ10 during a fatigue-inducing physical task

17 participants · 100 or 300 mg/day · 8 days

Small sample; strongest signal appeared at the higher dose.Read study
Coenzyme Q10Meta-analysis · 2022

CoQ10 and fatigue: pooled trial evidence

13 randomised trials · 1,126 participants

Pooled fatigue scores improved, but populations, doses and durations varied. Combination-product results were not significant; this does not establish a benefit for ava’s finished formula.Read analysis
Coenzyme Q10Crossover RCT · 2023

CoQ10 in post-COVID symptoms

121 randomised · 500 mg/day · 6 weeks per treatment

No significant symptom or quality-of-life benefit versus placebo. This clinical population and dose differ from ava’s 100 mg per serving; it is not evidence for treating long COVID.Read study
Acetyl-L-carnitineEvidence review · 2017

ALCAR for cognitive enhancement

Cochrane evidence review

Too little reliable evidence for conclusions in healthy adults.Read review
N-Acetyl-L-CysteineSystematic review · 2017

NAC and human cognition

Review of clinical evidence

The literature was heterogeneous and underpowered for firm conclusions.Read review
AstaxanthinRCT · 2010

Astaxanthin and oxidative biomarkers

0, 2 or 8 mg/day · 8 weeks

Dose-aligned biomarker research; not a direct performance outcome.Read study
AstaxanthinMeta-analysis · 2024

Fatigue, motor function and cognition

11 RCTs · 346 healthy participants

Cognitive accuracy was marginal; reaction time was not significant.Read analysis
Rhodiola roseaRCT · 2014

Rhodiola for shift-work fatigue

48 nursing students · 364–728 mg/day · 42 days

The primary result favoured placebo—an important contradictory finding.Read study
Rhodiola roseaEvidence review · 2024

Rhodiola and exercise performance

Narrative review · 16 human trials · 363 participants

Findings varied by exercise task, dose and extract. Studied regimens were generally above ava’s 75 mg per serving; benefits cannot be assumed for ava.Read review
Rhodiola roseaOpen-label study · 2017

Rhodiola: exploratory burnout-symptom study

118 participants · 400 mg/day · 12 weeks

Symptoms improved over time, but there was no placebo group to establish a treatment effect. The clinical population, WS 1375 extract and 400 mg dose differ from ava’s 75 mg serving.Read study
Panax ginsengCrossover trial · 2020

Ginseng, attention and perceived stress

Pilot human crossover research

Results are extract-specific and cannot be transferred automatically.Read study

Transparency before certainty.

The research above evaluates individual ingredients, often in different populations, forms, doses and durations. It does not prove that the finished Ava formula will produce identical outcomes.

Ava is a food supplement, not a medicine, and is not intended to diagnose, treat, cure or prevent disease.

Explore Focused Energy